{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:35:48Z","timestamp":1778297748772,"version":"3.51.4"},"reference-count":103,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2018-02320"],"award-info":[{"award-number":["2018-02320"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The effects of alcohol on gamma-aminobutyric acid (GABA) transmission are key for the development and maintenance of alcohol use disorder (AUD). Previous research consistently indicates that GABAB receptor agonists such as baclofen can attenuate addiction-related behaviors in preclinical models of AUD. More importantly, baclofen has also shown promise in clinical studies, particularly in severely alcohol-dependent patients. However, despite this promise, other clinical studies have not confirmed its efficacy and chiefly, larger clinical trials have not been conducted. Therefore, with the exception of France, baclofen is not approved for the treatment of AUD in any other country. Furthermore, it is also important to keep in mind that some patients treated with baclofen may experience important side-effects, including sedation, drowsiness and sleepiness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This short review will first discuss the history of baclofen for AUD treatment. We will then summarize preclinical behavioral results that have investigated the efficacy of GABAB PAMs for addiction treatment, with a special focus on our recent work that investigated the effects of ADX71441, a novel GABAB PAM, on several alcohol-related behaviors in rats that model important aspects of human AUD. Finally, in light of the recent criticism about the translational value of animal models of addiction, the specific translational potential of our work and of other preclinical studies that have unanimously reported the efficacy of GABAB PAMs to attenuate multiple alcohol-related behaviors will be discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Positive allosteric modulators (PAMs) of the GABAB receptor offer an attractive alternative approach to baclofen and have the potential to achieve mechanistic and therapeutic effects similar to GABAB agonists, while avoiding the tolerance and toxicity issues associated with baclofen. To date, all preclinical behavioral results have invariably shown the efficacy of GABAB PAMs for addiction treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Preclinical studies indicate that GABAB PAMs have a higher therapeutic index than orthosteric agonists, at least in terms of mitigating the sedative effects of GABAB agonism. This predicts that GABAB PAMs have a high translational potential in humans and merit being tested clinically, in particular in patients with severe AUD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/alcalc\/agab003","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T09:17:00Z","timestamp":1610183820000},"page":"139-148","source":"Crossref","is-referenced-by-count":26,"title":["Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder"],"prefix":"10.1093","volume":"56","author":[{"given":"Eric","family":"Augier","sequence":"first","affiliation":[{"name":"Center for Social and Affective Neuroscience, BKV, Link\u00f6ping University, Link\u00f6ping 58183, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"2021062213002438700_ref1","volume-title":"Addex and Indivior to Accelerate Additional GABA PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441","author":"Addex Therapeutics","year":"2019"},{"key":"2021062213002438700_ref2","first-page":"67","article-title":"Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence","volume":"24","author":"Addolorato","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"2021062213002438700_ref3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"2021062213002438700_ref4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0002-9343(01)01088-9","article-title":"Rapid suppression of alcohol withdrawal syndrome by baclofen","volume":"112","author":"Addolorato","year":"2002","journal-title":"Am J Med"},{"key":"2021062213002438700_ref5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.alcohol.2009.09.031","article-title":"Role of the GABA(B) receptor system in alcoholism and stress: Focus on clinical studies and treatment perspectives","volume":"43","author":"Addolorato","year":"2009","journal-title":"Alcohol"},{"key":"2021062213002438700_ref6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"2021062213002438700_ref7","article-title":"Baclofen in the treatment of patients with alcohol use disorder and other mental health disorders","volume":"9","author":"Agabio","year":"2018","journal-title":"Front Psych"},{"key":"2021062213002438700_ref8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","article-title":"Baclofen for the treatment of alcohol use disorder: The Cagliari Statement","volume":"5","author":"Agabio","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2021062213002438700_ref9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neubiorev.2010.04.005","article-title":"Validation crisis in animal models of drug addiction: Beyond non-disordered drug use toward drug addiction","volume":"35","author":"Ahmed","year":"2010","journal-title":"Neurosci Biobehav Rev"},{"key":"2021062213002438700_ref10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research","volume":"28","author":"Amato","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"2021062213002438700_ref11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"2021062213002438700_ref12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1530-0277.2003.tb04414.x","article-title":"Effect of baclofen on alcohol and sucrose self-administration in rats","volume":"27","author":"Anstrom","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"2021062213002438700_ref13","first-page":"1557","volume-title":"The Fifth Generation of Progress","author":"Anthony","year":"2002"},{"key":"2021062213002438700_ref14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.aao1157","article-title":"A molecular mechanism for choosing alcohol over an alternative reward","volume":"360","author":"Augier","year":"2018","journal-title":"Science"},{"key":"2021062213002438700_ref15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/npp.2017.53","article-title":"The GABAB positive allosteric modulator ADX71441 attenuates alcohol self-administration and relapse to alcohol seeking in rats","volume":"42","author":"Augier","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref16","doi-asserted-by":"crossref","DOI":"10.3791\/53305","article-title":"A method for evaluating the reinforcing properties of ethanol in rats without water deprivation, saccharin fading or extended access training","author":"Augier","year":"2017"},{"key":"2021062213002438700_ref17","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1007\/s00213-014-3605-3","article-title":"Wistar rats acquire and maintain self-administration of 20% ethanol without water deprivation, saccharin\/sucrose fading, or extended access training","volume":"231","author":"Augier","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref18","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","article-title":"Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial","volume":"26","author":"Beraha","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"2021062213002438700_ref19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-003-1769-3","article-title":"GABA(B) receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL\/6J mice","volume":"174","author":"Besheer","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0306-4522(02)00378-0","article-title":"Ventral tegmental area region governs GABA(B) receptor modulation of ethanol-stimulated activity in mice","volume":"115","author":"Boehm","year":"2002","journal-title":"Neuroscience"},{"key":"2021062213002438700_ref21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0165-6147(99)01413-3","article-title":"The \u2018ABC\u2019 of GABA receptors","volume":"21","author":"Bormann","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"2021062213002438700_ref22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/alcalc\/37.5.478","article-title":"A potential role for GABA(B) agonists in the treatment of psychostimulant addiction","volume":"37","author":"Brebner","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"2021062213002438700_ref23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s002130050825","article-title":"Differential effects of GABA(A) and GABA(B) agonists on sensitization to the locomotor stimulant effects of ethanol in DBA\/2 J mice","volume":"141","author":"Broadbent","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011592","article-title":"Cocaine is low on the value ladder of rats: Possible evidence for resilience to addiction","volume":"5","author":"Cantin","year":"2010","journal-title":"PLoS One"},{"key":"2021062213002438700_ref25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biopsych.2015.02.018","article-title":"Effect of the novel positive allosteric modulator of metabotropic glutamate receptor 2 AZD8529 on incubation of methamphetamine craving after prolonged voluntary abstinence in a rat model","volume":"78","author":"Caprioli","year":"2015","journal-title":"Biol Psychiatry"},{"key":"2021062213002438700_ref26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1037\/1064-1297.4.1.11","article-title":"Animal models of relapse","volume":"4","author":"Carroll","year":"1996","journal-title":"Exp Clin Psychopharmacol"},{"key":"2021062213002438700_ref27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0091-3057(98)00253-6","article-title":"Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice","volume":"63","author":"Chester","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"2021062213002438700_ref28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.alcohol.2015.04.010","article-title":"Anxiety-like behaviors at the end of the nocturnal period in sP rats with a \u201chistory\u201d of unpredictable, limited access to alcohol","volume":"49","author":"Colombo","year":"2015","journal-title":"Alcohol"},{"key":"2021062213002438700_ref29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/alcalc\/37.5.499","article-title":"The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats","volume":"37","author":"Colombo","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"2021062213002438700_ref30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-003-1397-y","article-title":"Baclofen suppresses motivation to consume alcohol in rats","volume":"167","author":"Colombo","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2021062213002438700_ref32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00505087","article-title":"Suppression of ethanol-induced locomotor stimulation by GABA-like drugs","volume":"295","author":"Cott","year":"1976","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2021062213002438700_ref33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0376-8716(01)00163-6","article-title":"GABA(B) receptor agonists for the treatment of drug addiction: A review of recent findings","volume":"65","author":"Cousins","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"2021062213002438700_ref34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0741-8329(87)90087-5","article-title":"GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats","volume":"4","author":"Daoust","year":"1987","journal-title":"Alcohol"},{"key":"2021062213002438700_ref35","article-title":"The use of very high-doses of baclofen for the treatment of alcohol-dependence: A case series","volume":"5","author":"Beaurepaire","year":"2014","journal-title":"Front Psych"},{"key":"2021062213002438700_ref36","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/adb.12688","article-title":"GABAB receptor positive allosteric modulators with different efficacies affect neuroadaptation to and self-administration of alcohol and cocaine","volume":"24","author":"Miguel","year":"2019","journal-title":"Addict Biol"},{"key":"2021062213002438700_ref37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28321-0","article-title":"Baclofen acts in the central amygdala to reduce synaptic transmission and impair context fear conditioning","volume":"8","author":"Delaney","year":"2018","journal-title":"Sci Rep"},{"key":"2021062213002438700_ref38","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.1099020","article-title":"Evidence for addiction-like behavior in the rat","volume":"305","author":"Deroche-Gamonet","year":"2004","journal-title":"Science"},{"key":"2021062213002438700_ref39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/332156a0","article-title":"A physiological role for GABAB receptors in the central nervous system","volume":"332","author":"Dutar","year":"1988","journal-title":"Nature"},{"key":"2021062213002438700_ref40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/syn.10238","article-title":"Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat","volume":"50","author":"Fadda","year":"2003","journal-title":"Synapse"},{"key":"2021062213002438700_ref41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/add.14764","article-title":"Are animal models of addiction useful?","volume":"115","author":"Field","year":"2020","journal-title":"Addiction"},{"key":"2021062213002438700_ref42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00471","article-title":"Drinking levels and profiles of alcohol addicted rats predict response to nalmefene","volume":"10","author":"Foo","year":"2019","journal-title":"Front Pharmacol"},{"key":"2021062213002438700_ref43","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"2021062213002438700_ref44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nbt1385","article-title":"Direct multiplexed measurement of gene expression with color-coded probe pairs","volume":"26","author":"Geiss","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2021062213002438700_ref45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiat"},{"key":"2021062213002438700_ref46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: A randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"key":"2021062213002438700_ref47","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pharmthera.2006.02.001","article-title":"Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms","volume":"111","author":"Heilig","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2021062213002438700_ref48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrn.2016.67","article-title":"Time to connect: Bringing social context into addiction neuroscience","volume":"17","author":"Heilig","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"2021062213002438700_ref49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/7854_2015_5006","article-title":"The need for treatment responsive translational biomarkers in alcoholism research","volume":"28","author":"Heilig","year":"2016","journal-title":"Curr Top Behav Neurosci"},{"key":"2021062213002438700_ref50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.134.3483.943","article-title":"Progressive ratio as a measure of reward strength","volume":"134","author":"Hodos","year":"1961","journal-title":"Science"},{"key":"2021062213002438700_ref51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1530-0277.2008.00817.x","article-title":"Attenuation of the stimulant response to ethanol is associated with enhanced ataxia for a GABA, but not a GABA, receptor agonist","volume":"33","author":"Holstein","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"2021062213002438700_ref52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s002130051069","article-title":"Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats","volume":"145","author":"Holter","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF02245527","article-title":"The role of GABAB receptors in mediating the stimulatory effects of ethanol in mice","volume":"111","author":"Humeniuk","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R","article-title":"Relapse rates in addiction programs","volume":"27","author":"Hunt","year":"1971","journal-title":"J Clin Psychol"},{"key":"2021062213002438700_ref55","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/adb.12306","article-title":"Rats quit nicotine for a sweet reward following an extensive history of nicotine use","volume":"22","author":"Huynh","year":"2017","journal-title":"Addict Biol"},{"key":"2021062213002438700_ref56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00213-013-3245-z","article-title":"Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice","volume":"231","author":"Hwa","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0741-8329(03)00068-5","article-title":"Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose","volume":"30","author":"Janak","year":"2003","journal-title":"Alcohol"},{"key":"2021062213002438700_ref58","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"key":"2021062213002438700_ref59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.17116\/jnevro20151156153-62","article-title":"Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan(R)) for alcohol dependence","volume":"115","author":"Krupitsky","year":"2015","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"2021062213002438700_ref60","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/npp.2014.306","article-title":"The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: A randomized controlled experimental medicine study","volume":"40","author":"Kwako","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref61","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/alcalc\/agx072","article-title":"Baclofen self-poisoning in the era of changing indication: Multicentric reports to a French Poison Control Centre","volume":"52","author":"Leger","year":"2017","journal-title":"Alcohol Alcohol"},{"key":"2021062213002438700_ref62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187152710790966614","article-title":"Effectiveness and safety of baclofen in the treatment of alcohol dependent patients","volume":"9","author":"Leggio","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2021062213002438700_ref63","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/npp.2013.17","article-title":"Extended heroin access increases heroin choices over a potent nondrug alternative","volume":"38","author":"Lenoir","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000698","article-title":"Intense sweetness surpasses cocaine reward","volume":"2","author":"Lenoir","year":"2007","journal-title":"PLoS One"},{"key":"2021062213002438700_ref65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neuropharm.2005.11.011","article-title":"The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats","volume":"50","author":"Liang","year":"2006","journal-title":"Neuropharmacology"},{"key":"2021062213002438700_ref66","first-page":"403","article-title":"Baclofen as a cocaine anti-craving medication: A preliminary clinical study","volume":"18","author":"Ling","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.alcohol.2012.11.002","article-title":"Reduction of alcohol intake by the positive allosteric modulator of the GABA(B) receptor, rac-BHFF, in alcohol-preferring rats","volume":"47","author":"Loi","year":"2013","journal-title":"Alcohol"},{"key":"2021062213002438700_ref68","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1530-0277.2009.01012.x","article-title":"Reduction of alcohol's reinforcing and motivational properties by the positive allosteric modulator of the GABA(B) receptor, BHF177, in alcohol-preferring rats","volume":"33","author":"Maccioni","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"2021062213002438700_ref69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40263-018-0596-3","article-title":"Potential of GABAB receptor positive allosteric modulators in the treatment of alcohol use disorder","volume":"33","author":"Maccioni","year":"2019","journal-title":"CNS Drugs"},{"key":"2021062213002438700_ref70","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00213-017-4644-3","article-title":"Suppressing effect of COR659 on alcohol, sucrose, and chocolate self-administration in rats: Involvement of the GABAB and cannabinoid CB1 receptors","volume":"234","author":"Maccioni","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.alcohol.2018.05.015","article-title":"Suppressing effect of CMPPE, a new positive allosteric modulator of the GABAB receptor, on alcohol self-administration and reinstatement of alcohol seeking in rats","volume":"75","author":"Maccioni","year":"2019","journal-title":"Alcohol"},{"key":"2021062213002438700_ref72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-007-0776-1","article-title":"Reducing effect of the positive allosteric modulator of the GABA(B) receptor, GS39,783, on alcohol self-administration in alcohol-preferring rats","volume":"193","author":"Maccioni","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.alcohol.2005.08.003","article-title":"Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats","volume":"36","author":"Maccioni","year":"2005","journal-title":"Alcohol"},{"key":"2021062213002438700_ref74","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00213-014-3815-8","article-title":"Inhibition of alcohol self-administration by positive allosteric modulators of the GABAB receptor in rats: Lack of tolerance and potentiation of baclofen","volume":"232","author":"Maccioni","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref75","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1471-4892(03)00107-3","article-title":"Allosteric modulators of G-protein-coupled receptors","volume":"3","author":"May","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"2021062213002438700_ref76","article-title":"Baclofen for alcohol use disorder","volume":"11","author":"Minozzi","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2021062213002438700_ref77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: Multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2021062213002438700_ref78","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","article-title":"High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial","volume":"25","author":"Muller","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2021062213002438700_ref79","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: A multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"2021062213002438700_ref80","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2005.10.005","article-title":"Reducing effect of the positive allosteric modulators of the GABA(B) receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats","volume":"525","author":"Orru","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"2021062213002438700_ref81","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: A systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","volume":"113","author":"Palpacuer","year":"2018","journal-title":"Addiction"},{"key":"2021062213002438700_ref82","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1369-1600.2008.00102.x","article-title":"Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats","volume":"13","author":"Quintanilla","year":"2008","journal-title":"Addict Biol"},{"key":"2021062213002438700_ref83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","article-title":"A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study","volume":"52","author":"Reynaud","year":"2017","journal-title":"Alcohol Alcohol"},{"key":"2021062213002438700_ref84","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/add.14927","article-title":"Titrated baclofen for high-risk alcohol consumption: A randomized placebo-controlled trial in out-patients with 1-year follow-up","volume":"115","author":"Rigal","year":"2020","journal-title":"Addiction"},{"key":"2021062213002438700_ref85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s002130050293","article-title":"Baclofen suppression of cocaine self-administration: Demonstration using a discrete trials procedure","volume":"131","author":"Roberts","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0893-133X(96)00002-4","article-title":"Baclofen attenuates the reinforcing effects of cocaine in rats","volume":"15","author":"Roberts","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref87","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1126\/science.1102496","article-title":"Neuroscience. Addicted rats","volume":"305","author":"Robinson","year":"2004","journal-title":"Science"},{"key":"2021062213002438700_ref88","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0163-1047(79)92061-2","article-title":"Long-term ethanol administration methods for rats: Advantages of inhalation over intubation or liquid diets","volume":"27","author":"Rogers","year":"1979","journal-title":"Behav Neural Biol"},{"key":"2021062213002438700_ref89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/alcalc\/agz082","article-title":"France grants an approval to baclofen for alcohol dependence","volume":"55","author":"Rolland","year":"2019","journal-title":"Alcohol Alcohol"},{"key":"2021062213002438700_ref90","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1038\/npp.2016.61","article-title":"The CRF1 antagonist verucerfont in anxious alcohol-dependent women: Translation of neuroendocrine, but not of anti-craving effects","volume":"41","author":"Schwandt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref91","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/npp.2016.94","article-title":"Lost in translation: CRF1 receptor antagonists and addiction treatment","volume":"41","author":"Shaham","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref92","first-page":"606","article-title":"Seizure sensitivity and GABAergic modulation of ethanol sensitivity in selectively bred FAST and SLOW mouse lines","volume":"287","author":"Shen","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2021062213002438700_ref93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3758\/BF03330642","article-title":"Increased preference for ethanol in rats following alcohol deprivation","volume":"8","author":"Sinclair","year":"1967","journal-title":"Psychonomic Science"},{"key":"2021062213002438700_ref94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0301-0082(91)90036-Z","article-title":"GABA receptor mechanisms in the central nervous system","volume":"36","author":"Sivilotti","year":"1991","journal-title":"Prog Neurobiol"},{"key":"2021062213002438700_ref95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(96)00174-4","article-title":"Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat","volume":"305","author":"Spanagel","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"2021062213002438700_ref96","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref97","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1124\/mol.60.5.963","article-title":"Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501","volume":"60","author":"Urwyler","year":"2001","journal-title":"Mol Pharmacol"},{"key":"2021062213002438700_ref98","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.103.053074","article-title":"N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: Novel allosteric enhancers of gamma-aminobutyric acidB receptor function","volume":"307","author":"Urwyler","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2021062213002438700_ref99","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00213-018-4893-9","article-title":"Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction","volume":"235","author":"Vengeliene","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"2021062213002438700_ref100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(01)00367-0","article-title":"From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol","volume":"26","author":"Wagner","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"2021062213002438700_ref101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1530-0277.2006.00259.x","article-title":"The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats","volume":"31","author":"Walker","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"2021062213002438700_ref102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.138.3537.143","article-title":"Experimental morphine addiction: Method for automatic intravenous injections in unrestrained rats","volume":"138","author":"Weeks","year":"1962","journal-title":"Science"},{"key":"2021062213002438700_ref103","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/alcalc\/article-pdf\/56\/2\/139\/38756170\/agab003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/alcalc\/article-pdf\/56\/2\/139\/38756170\/agab003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T13:02:03Z","timestamp":1624366923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/alcalc\/article\/56\/2\/139\/6131668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":103,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,9]]},"published-print":{"date-parts":[[2021,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agab003","relation":{},"ISSN":["0735-0414","1464-3502"],"issn-type":[{"value":"0735-0414","type":"print"},{"value":"1464-3502","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,2,9]]}}}